Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.

Background: Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by type and frequency of adverse events (AE), was similar to that of placebo.

Objective: As part of the risk management plan for bilastine, the safety profile of bilastine in the elderly was assessed.